) recently soared 28.42% on potential buyout rumors.
According to Bloomberg News,
) have shown interest in acquiring ViroPharma.
We remind investors that buyout rumors of ViroPharma have been
doing rounds since Jun 2013 when it was rumored that several
pharmaceutical companies have shown an interest in acquiring
ViroPharma given the company's orphan disease drug portfolio.
The company's key drugs include Cinryze for hereditary
angioedema (HAE), Plenadren for the treatment of adrenal
insufficiency (AI), Buccolam in Europe for the treatment of
pediatric seizures, and Vancocin for the treatment of C.
difficile- associated diarrhea (CDAD).
We note that ViroPharma's growth story currently revolves
around Cinryze, which is approved in the U.S. for routine
prophylaxis against angioedema attacks in adolescent and adult
patients with HAE.
Cinryze accounted for 76% of total sales in 2012. In the EU,
Cinryze received approval for routine prevention, pre-procedure
prevention and acute treatment of angioedema attacks in adults
and adolescents in 2011.
Cinrzye has been granted marketing exclusivity by the U.S.
Food and Drug Administration (FDA) until 2015 under the Orphan
Moreover, in Aug 2012, the FDA approved a Prior Approval
Supplement (PAS) to the Cinryze Biologics License Application
(BLA) for industrial scale manufacturing.
ViroPharma has begun commercializing Buccolam in Europe paving
the way for an additional revenue opportunity. Additionally, the
acquisition of Plenadren in 2011 expanded the company's orphan
disease commercial product portfolio.
Meanwhile, an interesting candidate in ViroPharma's pipeline
is maribavir, being developed for the treatment of
cytomegalovirus (CMV) infections in transplant recipients.
ViroPharma received orphan drug designation in the EU for
maribavir in Jun 2013 for the treatment of CMV in patients
suffering from impaired cell mediated immunity.
Maribavir was granted the same designation in the U.S. in May
2011 for the treatment of clinically significant CMV and disease
in at-risk patients.
We expect investor focus to remain on takeover updates. Shares
have gone up 67.2% on a year-to-date basis and we expect further
increase if the buyout rumors gather momentum.
ViroPharma currently carries a Zacks Rank #3 (Hold). Right
) looks attractive with a Zacks Rank #2 (Buy).
JAZZ PHARMACEUT (JAZZ): Free Stock Analysis
SHIRE PLC-ADR (SHPG): Free Stock Analysis
SANOFI-AVENTIS (SNY): Free Stock Analysis
VIROPHARMA (VPHM): Free Stock Analysis Report
To read this article on Zacks.com click here.